Nearly 80% of patients with moderate-to-severe atopic dermatitis maintained clear or almost clear skin with Lilly's lebrikizumab monthly maintenance dosing at two years

Media coverage

• Title	Nearly 80% of patients with moderate-to-severe atopic dermatitis maintained clear or almost clear skin with Lilly's lebrikizumab monthly maintenance dosing at two years
  Media name/outlet	PharmaBiz
  Country/Territory	India
  Date	21/10/23
  Persons	Emma Guttman